Physician profile
Jamie E Hendrix
NPI 1861992810
$718.05
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $686 · 2022: $18.59 · 2023: $13.70.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $124.28 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $100.39 | 2021 | |
| Novo Nordisk INC | $81.91 | 2021 | |
| Janssen Pharmaceuticals, INC | $64.90 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $60.50 | 2021 | |
| Glaxosmithkline, LLC. | $41.29 | 2021 | |
| Amarin Pharma, INC. | $39.50 | 2021 | |
| Merck Sharp & Dohme LLC | $30.93 | 2021-2023 | Vaxelis, Gardasil 9, Vaxneuvance |
| Novartis Pharmaceuticals Corporation | $25.56 | 2021 | |
| Sanofi-Aventis U.S. LLC | $22.79 | 2021 | |
| Pfizer INC. | $22.57 | 2021 | |
| Jazz Pharmaceuticals INC. | $19.62 | 2021 | |
| Abbott Laboratories | $18.59 | 2022 | |
| Arbor Pharmaceuticals, INC. | $17.42 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $13.50 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seqirus USA INC | $11.65 | 2021 | |
| Eisai INC. | $11.61 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $11.04 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jamie Hendrix listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.